Takip et
David Vanness
David Vanness
Professor of Health Policy and Administration, Penn State University
psu.edu üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
A typology of preferences for participation in healthcare decision making
KE Flynn, MA Smith, D Vanness
Social science & medicine 63 (5), 1158-1169, 2006
3182006
Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population
TM Gluecker, CD Johnson, LA Wilson, RL MacCarty, TJ Welch, ...
Gastroenterology 124 (4), 911-916, 2003
3052003
Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial
JM Huddleston, KH Long, JM Naessens, D Vanness, D Larson, ...
Annals of internal medicine 141 (1), 28-38, 2004
3002004
Effects of a hospitalist model on elderly patients with hip fracture
MP Phy, DJ Vanness, LJ Melton, KH Long, CD Schleck, DR Larson, ...
Archives of internal medicine 165 (7), 796-801, 2005
2222005
Unsuspected Extracolonic Findings at Screening CT Colonography: Clinical and Economic Impact1
PJ Pickhardt, ME Hanson, DJ Vanness, JY Lo, DH Kim, AJ Taylor, ...
Radiology 249 (1), 151-159, 2008
2202008
The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis
EA Pritts, DJ Vanness, JS Berek, W Parker, R Feinberg, J Feinberg, ...
Gynecological surgery 12, 165-177, 2015
2002015
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial
CV Paya, JA Wilson, MJ Espy, IG Sia, MJ DeBernardi, TF Smith, R Patel, ...
The Journal of infectious diseases 185 (7), 854-860, 2002
1732002
A health opportunity cost threshold for cost-effectiveness analysis in the United States
DJ Vanness, J Lomas, H Ahn
Annals of internal medicine 174 (1), 25-32, 2021
1292021
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
RP Insinga, DJ Vanness, JL Feliciano, K Vandormael, S Traore, T Burke
Journal of Medical Economics 21 (12), 1191-1205, 2018
842018
Estimating (quality‐adjusted) life‐year losses associated with deaths: With application to COVID‐19
AH Briggs, DA Goldstein, E Kirwin, R Meacock, A Pandya, DJ Vanness, ...
Health Economics 30 (3), 699-707, 2021
752021
Some cautions on the use of instrumental variables estimators in outcomes research: how bias in instrumental variables estimators is affected by instrument strength, instrument …
WH Crown, HJ Henk, DJ Vanness
Value in Health 14 (8), 1078-1084, 2011
722011
The cost‐effectiveness of acetaminophen, NSAIDs, and selective COX‐2 inhibitors in the treatment of symptomatic knee osteoarthritis
CC Kamath, HM Kremers, DJ Vanness, WM O'Fallon, RL Cabanela, ...
Value in Health 6 (2), 144-157, 2003
722003
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell …
RP Insinga, DJ Vanness, JL Feliciano, K Vandormael, S Traore, ...
Current medical research and opinion, 2019
682019
Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant …
EJ Bow, DJ Vanness, M Slavin, C Cordonnier, OA Cornely, DI Marks, ...
BMC infectious diseases 15, 1-11, 2015
652015
Predicting persistently high primary care use
JM Naessens, MA Baird, HK Van Houten, DJ Vanness, CR Campbell
The Annals of Family Medicine 3 (4), 324-330, 2005
592005
Investing in the disadvantaged: Assessing the benefits and costs of social policies
M Stegman, B Wolfe, N Tefft, CR Belfield, DJ Vanness, MS Salzer, ...
Georgetown University Press, 2009
582009
Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using …
M Bounthavong, A Zargarzadeh, DI Hsu, DJ Vanness
Value in Health 14 (5), 631-639, 2011
552011
Factors influencing clinical decisions to initiate thyroxine therapy for patients with mildly increased serum thyrotropin (5.1-10.0 mIU/L)
V Fatourechi, M Lankarani, PG Schryver, DJ Vanness, KH Long, GG Klee
Mayo Clinic Proceedings 78 (5), 554-560, 2003
522003
A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses
J Levy, M Rosenberg, D Vanness
Value in Health 21 (6), 677-684, 2018
502018
Employment and health insurance in long‐term liver transplant recipients
C Rongey, K Bambha, D Vanness, RA Pedersen, M Malinchoc, ...
American Journal of transplantation 5 (8), 1901-1908, 2005
482005
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20